Loading...
Owlet Inc. (OWLT) is a good buy for a beginner investor with a long-term horizon and $50,000-$100,000 available for investment. The company's strong growth potential, expanding product line, positive analyst ratings, and international expansion make it a compelling opportunity despite some short-term financial challenges.
The MACD is positive and expanding (0.149), indicating bullish momentum. RSI is neutral at 57.114, and moving averages are converging, showing no strong trend. The pre-market price of $11.48 is above the pivot level of $11.116, suggesting a potential upward move toward resistance levels at $11.719 and $12.092.

Analysts have raised price targets significantly, with TD Cowen and Northland projecting $19 and $20, respectively, and maintaining strong buy/outperform ratings.
International expansion of the Dream Sock into new markets like Australia, New Zealand, and South Africa.
FDA clearance for the Dream Sock, positioning it as a unique product in the health tech space.
Partnership with webAI and medical equipment providers to enhance product offerings.
Revenue growth of 44.60% YoY in Q3 2025.
Net income dropped significantly by -139.36% YoY, and EPS declined by -90.16%, reflecting profitability challenges.
Gross margin decreased slightly to 50.64%, down -2.97% YoY.
No significant hedge fund or insider trading activity, indicating neutral sentiment from institutional investors.
In Q3 2025, revenue increased by 44.60% YoY to $31.99M, showcasing strong growth. However, net income dropped to -$2.68M (-139.36% YoY), and EPS fell to -0.06 (-90.16% YoY), highlighting profitability issues. Gross margin decreased slightly to 50.64% (-2.97% YoY).
Analysts are bullish on Owlet, with TD Cowen and Northland raising price targets to $19 and $20, respectively, and maintaining buy/outperform ratings. William Blair initiated coverage with an outperform rating, citing strong growth prospects and promising new products. Analysts highlight the company's ability to take market share and its undervaluation compared to peers.